Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Reducing Adolescent Suicide Risk: Safety, Efficacy, and Connectome Phenotypes of Intravenous Ketamine

To see complete record on, please visit this link

Id: NCT04613453

Organisation Name: Yale University

Overal Status: Recruiting

Start Date: January 21, 2022

Last Update: August 23, 2022

Lead Sponsor: Yale University

Brief Summary: The purpose of this study is to determine if intravenous ketamine reduces suicidal thinking compared to an active placebo (midazolam) in adolescents who have treatment resistant depression and a recent history of a suicide event (defined as a suicide attempt, emergency room evaluation for suicidal thinking, or a transition to inpatient care for suicidality in the past 120 days).

The primary objective of this study is to determine whether ketamine reduces suicidal ideation (as measured via the C-SSRS, recent ideation scale) relative to an active control, midazolam, 48-hours after first administration in adolescents with TRD at high suicide risk.

  • Adolescent Suicide
  • Adolescent Depression

Total execution time in seconds: 0.30100798606873